CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 368 enrolled
Drug / intervention
Standard ART vs Mega ART +7 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • HIV infection confirmed by serology or virology
  • Age ≥18 years
  • Documented failure of ≥2 multi-drug regimens including all 3 drug classes (NRTI, NNRTI, PI) or documented resistance to drugs in each class
  • Currently on ART for ≥3 months and still receiving treatment
Key exclusion· 4
  • Pregnancy or breast-feeding or planned pregnancy
  • Poor protocol adherence anticipated or Mega-ART not feasible due to significant intolerance of multiple ARV drugs
  • Serious, uncontrolled major opportunistic infection within 14 days of screening
  • Expected early death from non-HIV disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00050089
NCT00050089N/ACompleted

CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA), Management of Patients With HIV Infection for Whom First and Second-line Highly Active Anti-Retroviral Therapy Has Failed

US Department of Veterans Affairs·interventional·Posted Nov 22, 2002·Updated Apr 23, 2015

In Brief

A clinical study evaluating No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP and Standard ART vs Mega ART for AIDS and HIV Infections. Completed, enrolled 368 participants across 30 sites in 2 countries.

Detailed Summary

This 'pragmatic' trial is a 2X2 open randomized study of patients in advanced HIV disease who have failed on conventional Highly Active Antiretroviral Therapy (HAART) regimens including all three classes of anti-HIV drugs. The first randomization will allocate patients to an intended 3-month antiretroviral drug-free period (ARDFP) or No ARDFP. The second randomization will allocate patients to Mega-ART (5+ drugs) or to Standard-ART (up to 4 drugs). The total study duration is 6.5 years with 5 years of intake and 1.5 year (minimum) of follow-up; median duration of patient follow-up is about 4 years. The target sample size is 390 patients and will provide 75% power to detect a 30% reduction in the hazard rate for the primary endpoint with mega-ART. Sixty-four sites will be participating in the trial--24 VA, 19 UK and 21 Canada.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAIDS, HIV Infections
CountriesPuerto Rico, United States

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 22, 2002
Enrollment StartJan 1, 2001
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 23.6 years ago

Interventions

No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFPother

Continuation or interruption of ART treatment

Standard ART vs Mega ARTdrug

Standard therapy vs Intensified therapy

No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFPother

Continuation or interruption of ART treatment

Standard ART vs Mega ARTdrug

Standard therapy vs Intensified therapy

No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFPother

Continuation or interruption of ART treatment

Standard ART vs Mega ARTdrug

Standard therapy vs Intensified therapy

No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFPother

Continuation or interruption of ART treatment

Standard ART vs Mega ARTdrug

Standard therapy vs Intensified therapy